State-of-the-art instrument enhances research in structural biology and protein analysis ZÜRICH / Dec 20, 2024 / Business Wire / Bruker announces the acceptance of a 1.2 GHz Ascend™ Nuclear Magnetic Resonance (NMR) spectrometer at the Swiss High-field NMR Facility , operated jointly by the University of Basel, ETH Zürich, and... Read More

Upgradable Large-Sample System Sets New Performance Standard for Cost-Effective AFMs SANTA BARBARA, Calif. / Dec 02, 2024 / Business Wire / At the 2024 MRS Fall Meeting & Exhibit , Bruker Corporation (Nasdaq: BRKR) today announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest... Read More

BILLERICA, Mass. / Nov 18, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on December 16, 2024 to stockholders of record as of December 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is... Read More

BILLERICA, Mass. / Nov 12, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Stifel 2024 Healthcare Conference in New York City Monday, November 18, 2024, at 8:35 a.m. Eastern Time Wolfe Research 2024 Healthcare Conference in New York City Tuesday, November 19, 2024, at 4:10... Read More

New Technology Expands Antibody Compatibility and Doubles Throughput while maintaining Tissue Integrity and Lack of Cross-Reactivity BILLERICA, Mass. / Nov 08, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced a major technological breakthrough in the CellScape™ Precise Spatial Proteomics platform for... Read More

Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenue up 3.8% yoy Q3 2024 GAAP diluted EPS $0.27; non-GAAP diluted EPS $0.60 Updated FY2024 guidance: Revenue $3.34 to $3.37 billion, implying Bruker organic revenue growth of 3% to 4%, and CER revenue growth of approximately 13% yoy Non-GAAP EPS of $2.36 - $2.41... Read More

BILLERICA, Mass. / Oct 28, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2024 financial results before market opening on Tuesday, November 5, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2024... Read More

Robust, Unbiased and Affordable 4D-Proteomics™ for Highest-Specificity Protein IDs & Quant Enables High-Fidelity Large-Scale Plasma Proteomics Typical Sequence Coverage >10 Peptides/protein and >100k Peptides per Cell-Line Proteome Ushers in HiFi Proteomics with High Isoform Specificity Novel diagonal-PASEF ® methods for... Read More

BILLERCA, Mass. / Oct 17, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the “928 Patent”), which has been asserted by 10x Genomics against NanoString’s CosMx® Spatial Molecular Imager (SMI) products in Europe. Today’s ruling follows the May 2024 decision of the... Read More

Biognosys’ proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing By offering the combination of NULISA™ affinity-based assays and TrueDiscovery ® mass spectrometry-based plasma profiling with P2 Plasma Enrichment, Biognosys offers the industry’s most comprehensive solutions for plasma proteomics Spectronaut ®... Read More

Bruker Spatial Biology Offers the Widest Range of Industry-leading Multiomic Spatial Biology Platforms to Scientists Globally BILLERICA, Mass. / Oct 11, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination... Read More

New Multiphoton Microscopy Module Enables Millisecond Neural Event Imaging at Single Neuron Resolution CHICAGO / Oct 07, 2024 / Business Wire / At the Neuroscience 2024 conference , Bruker Corporation (Nasdaq: BRKR) today announced the release of the OptoVolt ™ module to further expand the advanced neuroscience research... Read More

Combining Dynamic Biosensors’ Innovative Technologies with Bruker’s High-Performance SPR Portfolio to Establish a Leading Biosensors Business MUNICH / Oct 02, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Dynamic Biosensors GmbH , a pioneering company known for its breakthroughs in... Read More

BILLERICA, Mass. / Aug 23, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: 2024 Wells Fargo Healthcare Conference in Boston, MA Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time Morgan Stanley 22nd Annual Global Healthcare Conference in New York City Friday, September... Read More

Asia’s first 1.2 GHz NMR system empowers researchers to advance scientific discoveries SEOUL, South Korea / Aug 13, 2024 / Business Wire / Bruker Corporation is pleased to announce the successful installation and acceptance of a 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute... Read More

BILLERICA, Mass. / Aug 12, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on September 16, 2024 to stockholders of record as of September 2, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is... Read More

NovAliX is a drug discovery focused CRO with award-winning chemistry teams and one of the world’s most comprehensive biophysics platforms. Bruker and NovAliX intend to collaborate on enabling new paradigms in drug discovery, leveraging advanced biophysical methods, and NMR in particular, to structural, binding and functional... Read More

Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy Q2 2024 GAAP EPS $0.05; non-GAAP EPS $0.52, up 4.0% yoy Bruker increases FY 2024 revenue guidance to $3.38-$3.44 billion, now including the NanoString business; implies revenue growth of 14% to 16%, and organic revenue growth of 5% to 7% yoy BILLERICA, Mass. / Aug 06, 2024 / Business Wire / Bruker... Read More

BILLERICA, Mass. / Jul 31, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2024 financial results before market opening on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2024... Read More

The patent at issue was ruled invalid by the German Federal Patent Court in May 2024 BILLERICA, Mass. / Jul 18, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has posted a bond, as authorized by the Munich Higher Regional Court, in order to suspend an injunction that had been impacting sales of CosMx™ Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This... Read More

The Avance® 1.2 GHz NMR system will enable advanced studies of biomolecular structures and function in structural biology, pharmacology, and cellular biology BERLIN / Jul 02, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz... Read More

neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam 3D laser neofleX and MALDI HiPLEX-IHC technology enable protein tissue imaging Multiomics MSI correlation of targeted proteins... Read More

timsTOF Ultra 2 enables significant further improvements in deep, high-fidelity 4D-Proteomics™ of mammalian cells, cancer cell lines, or tissue biopsies With sensitivity to measure >1000 proteins on just 25 pg, the timsTOF Ultra 2 opens new cell and disease biology research windows into PBMCs, small immune cells, bacterial... Read More

BILLERICA, Mass. / May 31, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today it will present at the following conferences: 2024 Jefferies Global Healthcare Conference, New York, NY Thursday, June 6, 2024, at 7:30 a.m. Eastern Time Frank Laukien, Chairman, President and Chief Executive Officer Juergen Srega, President, Bruker CALID Group 45th Annual Goldman Sachs Global Healthcare Conference, Miami, FL... Read More

The proprietary P2 Plasma Enrichment method leverages a novel single-well, single particle-type enrichment method to achieve market-leading performance for unbiased, deep mass spectrometry-based plasma proteomics P2 now offers excellent quantitation and higher throughput for large-cohort biomarker or drug discovery studies, and clinical, epidemiological or population proteomics research P2 Plasma Enrichment is available as a... Read More

Spectronaut ® 19 offers significant improvements in identifications, candidate discovery, scalability for large-scale analysis, and support for novel workflows Novel TrueDiscovery ® P2 Plasma Enrichment method offers market-leading performance and superior economics for unbiased, deep plasma proteomics New TrueTarget ® high-throughput LiP-MS workflow enables large-scale drug target deconvolution screening with improved... Read More

BILLERICA, Mass. / May 29, 2024 / Business Wire / Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is expected to close on or... Read More

BILLERICA, Mass. / May 29, 2024 / Business Wire / Bruker Corporation (“Bruker” or the “Company”) (Nasdaq: BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing... Read More

BILLERICA, Mass. / May 16, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) will host an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) tomorrow May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook. The Investor Webinar will include... Read More

BILLERICA, Mass. / May 15, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on June 17, 2024 to stockholders of record as of June 3, 2024. About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR) Bruker is enabling... Read More

BILLERICA, Mass. / May 09, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it intends to hold an Investor Webinar from 10 am to about 12 noon Eastern Daylight Time (EDT) on May 17, 2024, to provide additional insights into its three recent acquisitions of Chemspeed, ELITech, and of the NanoString business. Bruker also expects to provide an update to its medium-term financial outlook. The Investor... Read More

NanoString, now a Bruker business, will promptly seek an end to the injunction impacting sales of CosMx SMI products in Germany BILLERICA, Mass. / May 07, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that the German Federal Patent Court has ruled in favor of NanoString Technologies Germany GmbH by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22).... Read More

Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy Q1 2024 GAAP EPS of $0.35; non-GAAP EPS of $0.53 Updated FY 2024 guidance: Revenue $3.29 to $3.35 billion, up $60 million from prior guidance, implying reported growth of 11% to 13% yoy. Organic revenue growth maintained at 5% to 7% yoy CER revenue growth of 12% to 14% yoy,... Read More

ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITech offers the proprietary, fully automated sample-to-answer (S2A) systems InGenius® and BeGenius® for molecular testing in mid-sized hospitals Diversified ELITech MDx assay portfolio focused on esoteric infectious disease testing ELITech has its R&D,... Read More

New MBT Pathfinder ® IVD robot for automated MALDI Biotyper ® target preparation New LiquidArray ® MTB-XDR panel for simultaneous detection of M. tuberculosis complex bacteria, and their resistances to five WHO-recommended second-line drugs against multidrug-resistant tuberculosis Pending ELITech acquisition has received all... Read More

BILLERICA, Mass. / Apr 25, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2024... Read More

NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healthcare BILLERICA, Mass. / Apr 22, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has entered into a definitive acquisition agreement with NanoString Technologies, Inc. , headquartered in Seattle, Washington, a leading provider of... Read More

ASILOMAR, Calif. / Apr 08, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large... Read More

ASILOMAR, Calif. / Apr 08, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) systems, today announces novel magnet technology and analytical solutions to support broad adoption of NMR in academic basic and clinical research, as well as in biopharma drug... Read More

Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomics Complementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys , a global leader in mass... Read More

BILLERICA, Mass. / Apr 01, 2024 / Business Wire / Bruker Corporation (NASDAQ: BRKR) has been selected as the Instrument Business Outlook ( IBO ) ‘Company of the Year’ for 2023. IBO cited Bruker’s double-digit organic revenue growth in 2023 in all major regions, and in all business groups, demonstrating a transformed portfolio and operational strength. The IBO recognition follows Bruker’s three consecutive years of... Read More

Novor V2.0 software with novel ML algorithm trained on HLA peptides yields immunopeptidome from de novo peptide sequencing with further improved IDs TwinScape™ digital-twin technology with iRT™ standards supports highest timsTOF performance with intelligent feedback – well beyond ‘just up-time’ New glyco-PASEF ® method for... Read More

BASEL, Switzerland / Mar 07, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions. This acquisition, first announced in January 2024, marks another... Read More

ELITechGroup is a differentiated, fast growing and profitable systems and assay provider for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology ELITechGroup offers the proprietary, fully automated sample-to-answer (S2A) molecular diagnostic (MDx) systems InGenius® and BeGenius® for mid-sized hospitals and esoteric testing Large and diversified ELITech MDx assay portfolio is focused on pathogens... Read More

BILLERICA, Mass. / Feb 26, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 29, 2024, at 8:45 a.m. Eastern Time TD Cowen 44th Annual Health Care Conference in Boston, MA Monday, March... Read More

BILLERICA, Mass. / Feb 16, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on March 15, 2024 to stockholders of record as of March 1, 2024. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries and... Read More

Q4 2023 revenues of $854.5 million, up 20.6% year-over-year (yoy); organic revenue up 15.9% yoy Q4 2023 GAAP EPS of $1.41, including a $0.99 per share gain on PhenomeX acquisition [1] ; Q4 2023 non-GAAP EPS of $0.70, down 5.4% yoy; pro forma non-GAAP EPS excluding PhenomeX acquisition up 8.1% yoy Full year 2023 revenues of $2.96 billion, up 17.1% yoy; organic revenue growth of 14.5% yoy Full year 2023 GAAP EPS of $2.90;... Read More

Nanophoton Strengthens Bruker’s Portfolio of Molecular Microscopy Research Solutions OSAKA, Japan / Feb 07, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation , a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton... Read More

Acquisition Complements Bruker’s Preclinical Imaging Portfolio with In-Vivo Optical Imaging TUCSON, Ariz. / Feb 06, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has acquired Spectral Instruments Imaging LLC , a leader in preclinical in-vivo optical imaging systems. This acquisition fills a... Read More

BILLERICA, Mass. / Feb 06, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com... Read More

Enables the Simultaneous Measurement of 64 Molecular Interactions BOSTON / Feb 05, 2024 / Business Wire / At the SLAS2024 International Conference and Exhibition , Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘ Triceratops ’ SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system... Read More

Chemspeed Accelerates Bruker’s Laboratory Automation and Digitalization Drive BASEL, Switzerland / Jan 25, 2024 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced a definitive agreement for the acquisition of Chemspeed Technologies AG , a Swiss provider of vendor-agnostic automated laboratory R&D and QC... Read More

The new CRO facility for proteomics services in Newton, Massachusetts ensures closer proximity to US customers Biognosys’ center of excellence for proteomics innovation at its headquarters near Zurich, Switzerland continues to offer its entire portfolio of services for discovery, targeted, and structural proteomics for all regions, including the Americas ZURICH, Switzerland and NEWTON, Mass., Jan. 23, 2024 (GLOBE NEWSWIRE)... Read More

MISSISSAUGA, Ontario / Jan 04, 2024 / Business Wire / Bruker (Nasdaq: BRKR) today announced the acquisition of Tornado Spectral Systems Inc. , a Canadian company specializing in process Raman instruments, primarily used in pharma and biotech quality control applications. Tornado, with over a decade of experience in innovative... Read More

Novel GHz-class NMR systems are enabling unprecedented life science and materials research in functional structural biology, drug discovery, metabolomics and cleantech research. COLUMBUS, Ohio / Dec 19, 2023 / Business Wire / Bruker Corporation , the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions... Read More

BILLERICA, Mass. / Nov 20, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on December 15, 2023 to stockholders of record as of December 1, 2023. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries... Read More

BILLERICA, Mass. / Nov 07, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 14, 2022 at 8:30 AM GMT (3:30 AM Eastern Time). A live audio... Read More

Q3 2023 revenues of $742.8 million, up 16.3% year-over-year (yoy); organic revenue up 10.9% yoy Q3 2023 GAAP EPS $0.60; non-GAAP EPS $0.74, up 12.1% yoy Bruker increases FY 2023 revenue guidance to $2.88-$2.91 billion; implies reported revenue growth of 14%-15% yoy, and organic revenue growth of 11.5%-12.5% yoy, with organic growth up 150 bps at the midpoint vs. prior guidance BILLERICA, Mass. / Nov 02, 2023 / Business Wire... Read More

BILLERICA, Mass. / Oct 27, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2023 financial results before market opening on Thursday, November 2, 2023. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2023... Read More

BILLERICA, Mass. / Oct 03, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools, for $108 million in cash. Bruker announced the agreement to acquire PhenomeX on August 17, 2023. PhenomeX is a functional cell biology company that provides single-cell biology research tools to deliver deep insights... Read More

Hysitron TI 990 Enables Materials Characterization with New Levels of Nanoindenting Performance COLUMBUS, Ohio / Oct 02, 2023 / Business Wire / At the annual Materials Science and Technology (MS&T23) conference, Bruker Corporation (Nasdaq: BRKR) today announced the release of the Hysitron TI 990 TriboIndenter ® , which brings... Read More

New AI-powered TIMSquant ™ software for CCS-enabled, label-free quantification scalable to thousands of samples Early midia-PASEF ® access for immunopeptidomics and PTMs on ultra-sensitive timsTOF Ultra for DDA-like precursor traceability in dia-PASEF Affordable, high-throughput ~3,500 PG plasma proteomics on timsTOF HT with... Read More

Library-free and machine learning-augmented data analysis with Spectronaut ® 18 yields industry-leading protein quantification and throughput for DIA proteomics Novel collaborative research using the TrueDiscovery ® and TrueTarget ® CRO services platforms demonstrates the quantitative precision and wide applicability of mass spectrometry proteomics for biomarker discovery and drug development Biognosys’ iRT Kit is... Read More

BILLERICA, Mass. / Aug 24, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 21 st annual Morgan Stanley Global Healthcare Conference in New York City. Gerald Herman, Executive Vice President & CFO will participate in a fireside chat on behalf of the Company on Wednesday, September 13 th , 2023 at 4:15 PM Eastern Time. A live audio webcast of the presentation will be... Read More

Acquisition initiates Bruker’s entry into functional single-cell biology research solutions BILLERICA, Mass. & EMERYVILLE, Calif. / Aug 17, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) and PhenomeX Inc. (Nasdaq: CELL) today announced that they have signed a definitive agreement for Bruker to acquire PhenomeX for $1.00 per share in an all-cash transaction. The proposed acquisition values PhenomeX at a total equity... Read More

BILLERICA, Mass. / Aug 14, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company’s common stock. The dividend will be paid on September 15, 2023 to stockholders of record as of September 1, 2023. About Bruker Corporation Bruker is enabling scientists to make breakthrough discoveries... Read More

ZUERICH, Switzerland / Jun 30, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the SciY™ platform of advanced, vendor-agnostic software solutions for data analysis, data management, research lab and bioproduction QC digitalization, and workflow automation in the life science industry and for biopharma companies. The new SciY platform combines and integrates high-performance lab software solutions for... Read More

KARLSRUHE, Germany / Jun 27, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASER TM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables... Read More

BILLERICA, Mass. / Jun 14, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today released its 2023 Sustainability Report, highlighting how Bruker’s spirit of ‘Innovation with Integrity’ is advancing science and technology, medicine and health, as well as safety and prosperity in a responsible, sustainable manner. The... Read More

timsTOF Ultra Further Advances Quantitative Spatial and Single-cell 4D-Proteomics and 4D-Lipidomics™, Immunopeptidomics, PTM and Protein-Protein Interactions Analysis - with Speed and Robustness timsTOF Ultra mass spectrometer enables ID of >5000 protein groups and >55k peptides at single-cell sensitivity (0.125 ng) with... Read More

ENRICH-iST enables unbiased enrichment of lower abundant plasma and serum proteins by 50% to more than 100% in human and rodent plasma proteomics in a cost-effective, fast 5-hour workflow ENRICH-iST utilizes non-functionalized paramagnetic microbeads supporting automated platforms ENRICH-iST enables protein enrichment and... Read More

BILLERICA, Mass. / Jun 02, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today it will present at the Jefferies 2023 Healthcare Conference in New York on Friday, June 9, 2023 at 9:00 am EDT. Presenting for the company will be Juergen Srega, President of the Bruker CALID Group. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at... Read More

BILLERICA, Mass. / May 31, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced the Company will host an Investor Day on June 15th, 2023, starting at 10:00 AM EDT, at Bruker’s Headquarters located at 40 Manning Road, Billerica, MA, with the live webcast starting at 11:00 AM EDT. Bruker’s 2023 Investor Day will provide a deeper look into the Company’s strategies and Project Accelerate 2.0 initiatives, with... Read More

BILLERICA, Mass. / May 15, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2023, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company’s common stock over a two-year period commencing on May 15, 2023. The share repurchase authorization permits shares to be repurchased under open market purchases, accelerated share... Read More

BILLERICA, Mass. / May 08, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced that is has closed the acquisition of ZONTAL Inc . ( www.zontal.io ), an innovative platform provider for the digital transformation of the analytical laboratory, and for integrated biopharma technical data solutions. This... Read More

Q1 2023 revenues of $685.3 million, up 15.2% year-over-year (yoy); organic revenue up 17.6% yoy Q1 2023 GAAP EPS $0.52; non-GAAP EPS $0.64, up 30.6% yoy Bruker increases FY 2023 guidance for revenue to $2.83-$2.88 billion and for non-GAAP EPS to $2.55-$2.60; implies revenue growth to 12%-14%, and organic revenue growth of 9% - 11% yoy BILLERICA, Mass. / May 04, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today... Read More

BILLERICA, Mass. / Apr 26, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2023 financial results before market opening on Thursday, May 4, 2023. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2023... Read More

Advancements in NMR enable deeper insights into life science, drug discovery, and cleantech ASILOMAR, Calif. / Apr 17, 2023 / Business Wire / At the Experimental Nuclear Magnetic Resonance Conference (ENC 2023), Bruker announces innovations for NMR spectroscopy in life science, pharma, and cleantech research to enable... Read More

MBT Mycobacteria IVD Kit optimizes sample preparation and comprehensive library of MBT HT Mycobacteria IVD Module MBT HT Filamentous Fungi IVD Module incorporates extensive fungal library with easy and effective sample preparation (MyT) New MBT Compass HT IVD software significantly increases speed for microbial identification,... Read More

Introduction of a FFPE workflow extends the tissue proteomics applications of PreOmics’ unique BeatBox™ technology Launch of novel FFPE workflow enables high-throughput, robust and fast processing of tissue samples Bruker and PreOmics to co-commercialize BeatBox workflows ORLANDO, Fla. / Apr 14, 2023 / Business Wire / At the... Read More

Enable Cloud Platform to be Available with Canopy CellScape System for High-Plex Spatial Biology ST. LOUIS & MENLO PARK, Calif. / Apr 12, 2023 / Business Wire / Canopy Biosciences, a Bruker Company , and Enable Medicine, today announced a partnership to provide Enable Medicine’s advanced analysis pipelines for spatial omics... Read More

COVENTRY, United Kingdom / Mar 17, 2023 / Business Wire / Bruker announces that the United Kingdom is expanding its fundamental research infrastructure with recent orders for two 1.2 GHz Avance ™ nuclear magnetic resonance (NMR) spectrometers for the University of Warwick and the University of Birmingham . Each institution already has a Bruker 1.0 GHz NMR spectrometer and will advance their capabilities further for research... Read More

CHICAGO / Mar 06, 2023 / Business Wire / At the 19th US HUPO, Bruker Corporation (Nasdaq: BRKR) announced important bioinformatics launches for 4D-Proteomics on the timsTOF platform: A novel de novo sequencing algorithm was developed in collaboration with Rapid Novor Inc., using over 1.7 million PASEF data-points to improve accuracy and speed for immunopeptidomics in real-time. The unmatched sensitivity of the timsTOF SCP... Read More

BILLERICA, Mass. / Feb 22, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City Thursday, March 2, 2023, at 9:30 a.m. Eastern Time Cowen 43 rd Annual Health Care Conference in Boston, MA Monday,... Read More

BILLERICA, Mass. / Feb 09, 2023 / Business Wire / Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the fiscal year ended December 31, 2022. Fourth Quarter 2022 Financial Results Bruker’s revenues for the fourth quarter of 2022 were $708.4 million, an increase of 3.6% compared to $683.5 million in the fourth quarter of 2021. In the fourth quarter of 2022, revenues increased... Read More

FÄLLANDEN, Switzerland / Feb 03, 2023 / Business Wire / Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022. Both new Ascend Evo 1.0 GHz NMR systems operate at 4.2 Kelvin without subcooling below liquid Helium temperatures, and as a result have ~65% lower liquid Helium... Read More

Adding Big-Data Management and High-Content Screening Solutions for Bioimaging Applications Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of ACQUIFER Imaging GmbH , a pioneer in big-data management solutions for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise... Read More

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut ® software tools for unbiased proteomics and epiproteomics Expected to benefit proteomics research, disease biomarker discovery, drug discovery and development, and clinical trials leveraging pharmacoproteomics With Bruker investments, Biognosys plans to open advanced US proteomics biomarker and drug discovery and development,... Read More

Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 41 st annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 9 th , 2023 at 10:30 AM Eastern Standard Time. A live audio... Read More